JD HEALTH
06618
ALI HEALTH
00241
KUAISHOU-W
01024
BILIBILI-W
09626
NTES-S
09999
(Q6)Sep 30, 2024 | (FY)Mar 31, 2024 | (Q6)Sep 30, 2023 | (FY)Mar 31, 2023 | (Q6)Sep 30, 2022 | (FY)Mar 31, 2022 | (Q6)Sep 30, 2021 | (FY)Mar 31, 2021 | (Q6)Sep 30, 2020 | (FY)Mar 31, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | 70.90%661.74M | 17.56%832.05M | 13.34%387.21M | -3.83%707.8M | -12.73%341.64M | -14.80%736M | -21.82%391.46M | -11.86%863.87M | 20.99%500.73M | 63.26%980.05M |
Operating income | 70.90%661.74M | 17.56%832.05M | 13.34%387.21M | -3.83%707.8M | -12.73%341.64M | -14.80%736M | -21.82%391.46M | -11.86%863.87M | 20.99%500.73M | 63.26%980.05M |
Cost of sales | -72.08%-583.66M | -16.98%-738.83M | -12.97%-339.18M | 0.08%-631.59M | 5.84%-300.23M | 17.28%-632.07M | 29.02%-318.85M | 12.22%-764.09M | -29.88%-449.2M | -79.83%-870.41M |
Operating expenses | -72.08%-583.66M | -16.98%-738.83M | -12.97%-339.18M | 0.08%-631.59M | 5.84%-300.23M | 17.28%-632.07M | 29.02%-318.85M | 12.22%-764.09M | -29.88%-449.2M | -79.83%-870.41M |
Gross profit | 62.58%78.08M | 22.32%93.22M | 15.98%48.03M | -26.67%76.21M | -42.97%41.41M | 4.17%103.93M | 40.93%72.62M | -9.00%99.78M | -24.20%51.53M | -5.71%109.64M |
Selling expenses | -70.90%-1.72M | -60.88%-1.49M | -117.97%-1.01M | -316.14%-928K | -579.41%-462K | ---223K | 99.56%-68K | ---- | -55.30%-15.31M | -1,546.73%-21.18M |
Administrative expenses | -10.74%-40.38M | -1.21%-76.23M | -0.00%-36.46M | -13.97%-75.32M | -23.49%-36.46M | 3.65%-66.09M | 42.91%-29.53M | 37.86%-68.59M | -7.14%-51.72M | -68.32%-110.39M |
Revaluation surplus | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -84.10%2.66M | 3,118.54%13.2M |
-Changes in the fair value of other assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -84.10%2.66M | 3,118.54%13.2M |
Impairment and provision | -1,315.72%-5.57M | -40.90%302K | --458K | 120.97%511K | ---- | -335.96%-2.44M | 68.59%-354K | 71.99%-559K | ---1.13M | ---2M |
-Impairment of property, machinery and equipment | ---5.96M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Other impairment is provision | -15.28%388K | -40.90%302K | --458K | 120.97%511K | ---- | -335.96%-2.44M | 68.59%-354K | 71.99%-559K | ---1.13M | ---2M |
Special items of operating profit | 104.66%12.25M | -22.94%20.13M | -68.01%5.98M | 172.25%26.13M | 536.77%18.7M | -76.49%9.6M | -89.10%2.94M | -10.86%40.83M | 140.37%26.95M | 2,269.53%45.8M |
Operating profit | 150.96%42.65M | 35.09%35.93M | -26.70%17M | -40.60%26.6M | -49.16%23.19M | -37.33%44.78M | 251.42%45.6M | 103.69%71.46M | -65.64%12.98M | -32.21%35.08M |
Financing cost | 25.72%-10.4M | 46.80%-14.4M | -68.39%-14M | -281.03%-27.06M | -61.33%-8.32M | -47.81%-7.1M | -6.42%-5.15M | 36.59%-4.8M | -112.04%-4.84M | -389.41%-7.58M |
Share of profits of associates | 184.34%210K | -242.67%-2.48M | -53.70%-249K | -51.34%1.74M | -106.77%-162K | -81.21%3.57M | -54.35%2.39M | 1,519.06%19.02M | 9,141.38%5.24M | 29,475.00%1.18M |
Earning before tax | 1,082.62%32.46M | 1,386.58%19.06M | -81.34%2.75M | -96.89%1.28M | -65.67%14.71M | -51.84%41.26M | 220.26%42.84M | 198.73%85.68M | -62.24%13.38M | -42.87%28.68M |
Tax | -5,115.49%-10.68M | -405.13%-7.97M | 106.27%213K | 131.64%2.61M | 55.79%-3.4M | -19.68%-8.25M | -94.19%-7.68M | -11.66%-6.89M | 32.66%-3.96M | 41.09%-6.17M |
After-tax profit from continuing operations | 636.31%21.78M | 184.90%11.09M | -73.85%2.96M | -88.21%3.89M | -67.82%11.31M | -58.10%33.01M | 273.21%35.16M | 250.04%78.78M | -68.12%9.42M | -43.34%22.51M |
After-tax profit from non-continuing business | ---- | ---- | ---- | ---- | ---- | 60.16%-16.14M | ---56.94M | ---40.51M | ---- | ---- |
Earning after tax | 636.31%21.78M | 184.90%11.09M | -73.85%2.96M | -76.92%3.89M | 151.95%11.31M | -55.93%16.87M | -331.14%-21.78M | 70.04%38.27M | -68.12%9.42M | -43.34%22.51M |
Minority shareholders should account for profits from continuing business | ---- | ---- | ---- | ---- | ---- | -96.22%-1.56M | ---1.5M | ---793K | ---- | ---- |
Minority shareholders should account for non-continuing business profits | ---- | ---- | ---- | ---- | ---- | -105.69%-21.09M | ---8.75M | ---10.25M | ---- | ---- |
Minority profit | -55.95%-10.64M | -34.14%-10.98M | -27.56%-6.82M | 63.85%-8.19M | 47.80%-5.35M | -105.01%-22.65M | -6.94%-10.25M | -432.64%-11.05M | -2,027.57%-9.58M | -55.12%-2.07M |
Shareholders should account for profits from continuing business | ---- | ---- | ---- | ---- | ---- | -56.50%34.56M | --36.66M | --79.46M | ---- | ---- |
Shareholders should account for profits from non-continuing business | ---- | ---- | ---- | ---- | ---- | 116.42%4.95M | ---48.19M | ---30.14M | ---- | ---- |
Profit attributable to shareholders | 231.48%32.42M | 82.73%22.07M | -41.30%9.78M | -69.43%12.08M | 244.49%16.66M | -19.88%39.51M | -160.69%-11.53M | 100.64%49.32M | -34.60%19M | -40.13%24.58M |
Basic earnings per share | 200.00%0.06 | 100.00%0.04 | -33.33%0.02 | -75.00%0.02 | 250.00%0.03 | -20.00%0.08 | -150.00%-0.02 | 100.00%0.1 | -33.33%0.04 | -37.50%0.05 |
Diluted earnings per share | 200.00%0.06 | 100.00%0.04 | -33.33%0.02 | -75.00%0.02 | 250.00%0.03 | -20.00%0.08 | -150.00%-0.02 | 100.00%0.1 | -33.33%0.04 | -37.50%0.05 |
Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Shin-Ei Zhonghe (Hong Kong) Certified Public Accountants Limited | -- | Shin-Ei Zhonghe (Hong Kong) Certified Public Accountants Limited | -- | Shin-Ei Zhonghe (Hong Kong) Certified Public Accountants Limited | -- | Shin-Ei Zhonghe (Hong Kong) Certified Public Accountants Limited | -- | Shin-Ei Zhonghe (Hong Kong) Certified Public Accountants Limited |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.